These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1153 related items for PubMed ID: 19757985

  • 1. Impact of delaying 5-alpha reductase inhibitor therapy in men on alpha-blocker therapy to treat BPH: assessment of acute urinary retention and prostate-related surgery.
    Naslund M, Eaddy MT, Hogue SL, Kruep EJ, Shah MB.
    Curr Med Res Opin; 2009 Nov; 25(11):2663-9. PubMed ID: 19757985
    [Abstract] [Full Text] [Related]

  • 2. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate.
    Naslund MJ, Miner M.
    Clin Ther; 2007 Jan; 29(1):17-25. PubMed ID: 17379044
    [Abstract] [Full Text] [Related]

  • 3. A large retrospective analysis of acute urinary retention and prostate-related surgery in BPH patients treated with 5-alpha reductase inhibitors: dutasteride versus finasteride.
    Issa MM, Runken MC, Grogg AL, Shah MB.
    Am J Manag Care; 2007 Feb; 13 Suppl 1():S10-6. PubMed ID: 17295600
    [Abstract] [Full Text] [Related]

  • 4. Clinical progression, acute urinary retention, prostate-related surgeries, and costs in patients with benign prostatic hyperplasia taking early versus delayed combination 5α-reductase inhibitor therapy and α-blocker therapy: a retrospective analysis.
    Morlock R, Goodwin B, Gomez Rey G, Eaddy M.
    Clin Ther; 2013 May; 35(5):624-33. PubMed ID: 23583026
    [Abstract] [Full Text] [Related]

  • 5. 5-Alpha reductase inhibition provides superior benefits to alpha blockade by preventing AUR and BPH-related surgery.
    Boyle P, Roehrborn C, Harkaway R, Logie J, de la Rosette J, Emberton M.
    Eur Urol; 2004 May; 45(5):620-6; discussion 626-7. PubMed ID: 15082205
    [Abstract] [Full Text] [Related]

  • 6. BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE.
    Roehrborn CG.
    BJU Int; 2008 Mar; 101 Suppl 3():17-21. PubMed ID: 18307681
    [Abstract] [Full Text] [Related]

  • 7. Drug Insight: 5alpha-reductase inhibitors for the treatment of benign prostatic hyperplasia.
    Marberger M.
    Nat Clin Pract Urol; 2006 Sep; 3(9):495-503. PubMed ID: 16964191
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Long-term results of medical treatment in benign prostatic hyperplasia.
    Kim CI, Chang HS, Kim BK, Park CH.
    Urology; 2006 Nov; 68(5):1015-9. PubMed ID: 17095071
    [Abstract] [Full Text] [Related]

  • 10. Symptom deterioration during treatment and history of AUR are the strongest predictors for AUR and BPH-related surgery in men with LUTS treated with alfuzosin 10 mg once daily.
    Emberton M, Elhilali M, Matzkin H, Harving N, van Moorselaar J, Hartung R, Alcaraz A, Vallancien G, Alf-One Study Group.
    Urology; 2005 Aug; 66(2):316-22. PubMed ID: 16098361
    [Abstract] [Full Text] [Related]

  • 11. Managing the progression of lower urinary tract symptoms/benign prostatic hyperplasia: therapeutic options for the man at risk.
    Emberton M, Zinner N, Michel MC, Gittelman M, Chung MK, Madersbacher S.
    BJU Int; 2007 Aug; 100(2):249-53. PubMed ID: 17617135
    [Abstract] [Full Text] [Related]

  • 12. The natural history of benign prostatic hyperplasia.
    Fitzpatrick JM.
    BJU Int; 2006 Apr; 97 Suppl 2():3-6; discussion 21-2. PubMed ID: 16507045
    [Abstract] [Full Text] [Related]

  • 13. Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial.
    Roehrborn CG, Barkin J, Siami P, Tubaro A, Wilson TH, Morrill BB, Gagnier RP.
    BJU Int; 2011 Mar; 107(6):946-54. PubMed ID: 21332630
    [Abstract] [Full Text] [Related]

  • 14. Combination therapy with dutasteride and tamsulosin in men with moderate-to-severe benign prostatic hyperplasia and prostate enlargement: the CombAT (Combination of Avodart and Tamsulosin) trial rationale and study design.
    Siami P, Roehrborn CG, Barkin J, Damiao R, Wyczolkowski M, Duggan A, Major-Walker K, Morrill BB, CombAT study group.
    Contemp Clin Trials; 2007 Nov; 28(6):770-9. PubMed ID: 17761460
    [Abstract] [Full Text] [Related]

  • 15. The impact of medical therapy on surgery for benign prostatic hyperplasia: a study comparing changes in a decade (1992-2002).
    Vela-Navarrete R, Gonzalez-Enguita C, Garcia-Cardoso JV, Manzarbeitia F, Sarasa-Corral JL, Granizo JJ.
    BJU Int; 2005 Nov; 96(7):1045-8. PubMed ID: 16225526
    [Abstract] [Full Text] [Related]

  • 16. Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in relation to the patient's risk profile for progression.
    Trachtenberg J.
    BJU Int; 2005 Jun; 95 Suppl 4():6-11. PubMed ID: 15871730
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Prostate size influences the outcome after presenting with acute urinary retention.
    McNeill AS, Rizvi S, Byrne DJ.
    BJU Int; 2004 Sep; 94(4):559-62. PubMed ID: 15329112
    [Abstract] [Full Text] [Related]

  • 20. Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice.
    Vallancien G, Emberton M, Alcaraz A, Matzkin H, van Moorselaar RJ, Hartung R, Harving N, Elhilali M, ALF-ONE Study Group.
    BJU Int; 2008 Apr; 101(7):847-52. PubMed ID: 18321317
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 58.